Drug firm Zydus Cadila today said it has filed an application with the US Food and Drug Administration (FDA) for its molecule being developed at the Zydus Research Centre for treating a disease concerning the elevation of the level of fats in blood.
"The group has already filed an IND (Investigational New Drug) application for ZYT1 in India and is currently in Phase I clinical trials," the company said in a filing to the Bombay Stock Exchange.
The disease for which the application has been made is called dyslipidemia.
With ZYT1 entering the first phase of clinical trials, it has promising commercial potential because of an absence of effective treatment for dyslipidemia patients, Zydus Cadila Chairman and Managing Director Pankaj Patel said.
Designed and developed at the Zydus Research Centre, ZYT1 is a novel, anti-dyslipidemic agent which may provide an alternative to statin (a class of drugs that lower cholestorol), the company said.
